Gil Fridberg

Dr. Gil Fridberg


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2024 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
RRRon Ram
Ron Ram
OAOdelia Amit
Odelia Amit
CPChava Perry
Chava Perry
YHYair Herishanu
Yair Herishanu
IAIrit Avivi
Irit Avivi
OBOfrat Beyar-Katz
Ofrat Beyar-Katz
Patients with large B-cell lymphoma (LBCL) in stable or progressive disease (SD/PD) at lymphodepletion prior to chimeric antigen receptor T cell (CAR-T) therapy have an inferior outcome. we hypothesized that enhancing in-vivo expansion of CAR-T cells could overcome this grim prognosis leading to improved outcomes. We conducted a phase 2 prospective trial (NCT05385263) investigating the addition of nivolumab to enhance CAR-T cell expansion and response in patients with SD/PD-LBCL. Eligible patients received 1 dose of nivolumab between day +5 and +9 post CAR-T infusion. An additional dose of nivolumab was administered on day +19 only to patients whose CAR-T cell levels in peripheral blood were below 100 cells/µL at day +7. Twenty patients were enrolled and received anti-CD19 CAR-T (Axicabtagene ciloleucel, n=12; tisagenlecleucel, n=8). Eight were ineligible to receive nivolumab due to active CAR-T-associated toxicities. Overall, the protocol was safe. One-month PET-CT showed an 84% overall response rate (complete response, 53%). The cumulative incidence of progression-free survival at 6 and 12 months were 50% (95%CI36%-64%) and 42% (95%CI26%-58%), respectively. The cumulative incidence of overall survival at 6 and 12 months were 85% (95%CI72%-98%) and 51% (95%CI31%-71%), respectively. Nivolumab administration significantly reduced PD-1 expression on all immune cells. CAR-T cell expansion was similar between nivolumab-eligible and non-eligible patients. Notably, there was a significant enrichment of CD45RO-CD27+ CD8+ cells and CD45RO-CD27+ CD8+ CAR-T cells in the nivolumab-eligible group compared to those ineligible, suggesting that specific cell enrichment could potentially contribute to an enhanced response rate. We conclude that the addition of nivolumab based on CAR-T cell expansion in patients with SD/PD-LBCL is safe and yields promising early response rates.

28 November 2023 in Cancers
Verified
Journal Article
Open access
PDF file
GFGil Fridberg
Gil Fridberg
GHGalit Horn
Galit Horn
ALAnat Globerson Levin
Anat Globerson Levin
DBDan Benisty
Dan Benisty
SKSigi Kay
Sigi Kay
BKBen-Zion Katz
Ben-Zion Katz
Chimeric Antigen Receptor T-cell (CAR T) therapy has become the preferable treatment in relapsed/refractory diffuse large B-cell lymphomas (DLBCL) patients. Detection of CAR Ts in peripheral blood smear (PBS) is challenging due to insufficient data regarding their morphology and low sensitivity. The morphological evolution of CAR Ts along their production process, and in patients, was established by Full-Field Morphology (FFM), a novel digital microscopy approach that provides highly sensitive PBS analysis. At day 8 of production, 42.7 ± 10.8% of the CAR T transduced cells exhibited activated morphology compared with 9.3 ± 3.8% in untransduced cells. Moreover, engagement of transduced CAR Ts with target cells resulted in further morphological transformation into activated morphology (83 ± 5.6% of the cells). In patients, the average number of day 5 CAR Ts, and their sustained presence, were significantly higher in patients obtaining complete response. A high number of activated morphology CAR Ts at day 14 was associated with prolonged cytokine release storm. Overall, CAR Ts exhibited heterogeneous morphology, with the activated morphology attributed predominantly to transduced cells following engagement with target cells. Post-transfusion CAR T detection was associated with increased complete responses. FFM CAR T surveillance in PBS may serve as a simple inexpensive method to provide clinically relevant insights into this treatment modality.

17 October 2024 in Cancers
Verified
Journal Article
Open access
PDF file
GFGil Fridberg
Gil Fridberg
OAOdelia Amit
Odelia Amit
CKChen Karni
Chen Karni
DTDina Tshernichovsky
Dina Tshernichovsky
DSDavid Shasha
David Shasha
RRRon Ram
Ron Ram
Objectives—chronic graft vs. host disease (cGVHD) is associated with substantial morbidity and mortality. We aimed to analyze advances in treatment strategy and outcomes during the last decade due to the incorporation of novel immunosuppressive therapy (IST) drugs in the armamentarium. Methods—we retrospectively analyzed all patients > 18 years with cGVHD after their first hematopoietic cell transplantation (HCT) between 2012 and 2020 (n = 91), divided into three treatment periods: 2012–2014, 2015–2017, and 2018–2020 (groups 1, 2, and 3, respectively). Results—mean cumulative steroid dose and dose/total cGVHD-treatment days was lower in groups 2–3 compared to 1 (p = 0.008 and p = 0.042, respectively). The median IST-free survival was 79 (95%CI54–94) months, with more patients in group 3 (47% (95%CI 25–54%) discontinuing IST at 3 years, p = 0.1). Groups 2–3 compared to 1 had better glycemic control (p < 0.01), higher bone density (p = 0.06), and fewer cardiovascular events. The number of admissions/patient dropped from 0.7/year in group 1 to 0.24/year and 0.36/year in groups 2–3, respectively (p = 0.36). Employment reintegration was higher in groups 2–3 compared with 1 (p = 0.05) and so was earlier return to work (p = 0.01). There were no differences in survival outcomes. Conclusions—the incorporation of novel agents appears to be associated with reduced overall steroid burden, improved cGVHD control, and fewer long-term side effects.

12 February 2026 in Haematologica
Verified
Journal Article
Open access
GFGil Fridberg
Gil Fridberg
OAOdelia Amit
Odelia Amit
YSYehonathan Sherf
Yehonathan Sherf
CPChava Perry
Chava Perry
YHYair Herishanu
Yair Herishanu
RRRon Ram
Ron Ram
CAR-T has transformed relapsed/refractory LBCL treatment, with CD28-based products yielding rapid responses but higher ICANS rates. With Axicabtagene-ciloleucel and Brexucabtagene-autoleucel, overall and severe ICANS reach 78% and 35%, respectively. Older adults are vulnerable, yet mitigation strategies remain lacking. We aimed to develop and implement a standardized ICANS mitigation protocol for older adults receiving CD28- based anti-CD19 CAR-T, addressing this critical gap. We conducted a single-arm prospective pilot study in patients ≥75yr or ≥65 with additional risk factor receiving CD28-based CAR-T. The protocol included levetiracetam and thiamine prophylaxis, early grade-based corticosteroids and anakinra for grade ≥3 and refractory ICANS – defined as no improvement within 24hr. Endpoints were ICANS duration, refractoriness, response and toxicity. Forty-five patients met eligibility; median age 75 (65-86), 78% had ECOG ≥2 and 42% with neurologic comorbidity. Overall, grade ≥3, and refractory ICANS developed in 67%, 31%, and 20%, respectively. Median ICANS duration was 4 days, shorter than previous cohorts. Disease and patients’ characteristics did not predict ICANS metrics, excluding LDH showing trend for severe ICANS (p=0.07). mEASIX and ICANS-PSS scores were not predictive; expansion was not compromised. Cumulative steroids associated with infections (p=.002) and NRM (p

25 July 2026 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
GFGil Fridberg
Gil Fridberg
OAOdelia Amit
Odelia Amit
MGMuhammad Ganayem
Muhammad Ganayem
CPChava Perry
Chava Perry
YHYair Herishanu
Yair Herishanu
RRRon Ram
Ron Ram

17 February 2026 in Transplantation and Cellular Therapy
Verified
Journal Article
Closed access
AKAnwar Khatib
Anwar Khatib
AGAmir Grau
Amir Grau
OAOdelia Amit
Odelia Amit
TZTsila Zuckerman
Tsila Zuckerman
GFGil Fridberg
Gil Fridberg
RRRon Ram
Ron Ram